Improvement of endothelial dysfunction in experimental heart failure by chronic RAAS-blockade: ACE-inhibition or AT1-receptor blockade?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue SUPPL. 1, 2001, Pages

  Wagenaar, Lodewijk J ^a,b   Buikema, Hendrik ^b   Pinto, Yigal M ^a   Van Gilst, Wiek H ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ACE inhibition; AT1 receptor blockade; Endothelial function; Heart failure; Myocardial infarction; Oxidative stress; Rats

Indexed keywords

EID: 0345893933     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/14703203010020011101     Document Type: Article

References (33)

1. Teerlink JR, Clozel M, Fischli W, Clozel JP. Temporal evolution of endothelial dysfunction in a rat model of chronic heart failure. J Am Coll Cardiol 1993;22:615-20.
2. Thuillez C, Mulder P, Elfertak L et al. Prevention of endothelial dysfunction in small and large arteries in a model of chronic heart failure. Effect of angiotensin converting enzyme inhibition. Am J Hypertens 1995;8:7S-12S.
3. Buikema H, van Veldhuisen DJ, Hegeman H, van Gilst WH. Early pharmacologic intervention may prevent the deterioration in endothelial function after experimental myocardial infarction in rats: effects of ibopamine and captopril. J Card Fail 1997;3:125-32.
4. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-96.
5. Drexler H, Hayoz D, Munzel T, Just H, Zelis R, Brunner HR. Endothelial function in congestive heart failure. Am Heart J 1993;126:761-4.
6. Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66:22D-30D.
7. Pinto YM, Buikema H, van Gilst WH. Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses. Clin Exp Hypertens 1995;17:441-68.
8. Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
9. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18:655-73.
10. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 1999;100:292-8.
11. Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc Res 1999;43:838-49.
12. Ontkean MT, Gay R, Greenberg B. Effects of chronic captopril therapy on endothelium-derived relaxing factor in heart failure. J Am Coll Cardiol 1992;19:207A (abstract).
13. 1-antagonist, and combined treatment in mice with heart failure. J Cardiovasc Pharmacol 2000;36:472-80.
14. Schieffer B, Wirger A, Meybrunn M et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-82.
15. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol 1996;27:714-9.
16. Pinto YM, de Smet BG, van Gilst WH et al. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 1993;27:1933-8.
17. de Vries RJ, Anthonio R, van Veldhulsen DJ, Scholtens E, Buikema H, van Gilst WH. Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction. J Cardiovasc Pharmacol 1997;30:683-9.
18. van Gilst WH, van Veldhulsen DJ, Hegeman H et al. Effect of ibopamine on ventricular remodeling after experimental myocardial infarction: a comparison with captopril. J Cardiovasc Pharmacol 1994;24:171-4.
19. van Gilst WH, de Graeff PA, de Leeuw MJ, Scholtens E, Wesseling H. Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo-and endogenous nitrovasodilators. J Cardiovasc Pharmacol 1991;18:429-36.
20. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996;17:787-94.
21. Buikema H, Pinto YM, van Geel PP et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol 1997;29:684-91.
22. Pfeffer MA, Pfeffer JM, Fishbein MC et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-12.
23. Tsunoda K, Hodsman GP, Sumithran E, Johnston CI. Atrial natriuretic peptide in chronic heart failure in the rat: a correlation with ventricular dysfunction. Circ Res 1986;59:256-61.
24. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
25. Malmsjo M, Bergdahl A, Zhao XH et al. Enhanced acetylcholine and P2Y-receptor stimulated vascular EDHF-dilatation in congestive heart failure. Cardiovasc Res 1999;43:200-9.
26. Pinto YM, Bader M, Pesquero JB et al. Increased kallikrein expression protects against cardiac ischemia. FASEB J 2000;14:1861-3.
27. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6.
28. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI40-VI48.
29. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
30. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
31. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
32. Ontkean MT, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 1991;69:1088-96.
33. Buikema H, Monnink SH, Tio RA, Crijns HJ, de Zeeuw D, van Gilst WH. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000; 130:1999-2007.